Cited In for PMID: 21573251

Year	Number of Results
2011	1
2012	1
2013	6
2014	1
2016	1
2020	1
2021	2
2022	1
2023	1
2024	0

1

Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications.

Murdaca G, Colombo BM, Puppo F. Murdaca G, et al. Drugs Today (Barc). 2011 Apr;47(4):277-88. doi: 10.1358/dot.2011.47.4.1576692. Drugs Today (Barc). 2011. PMID: 21573251 Review.

2

Risk of all-cause and cause-specific mortality associated with immune-mediated inflammatory diseases in Korea.

Kwon OC, Lee SY, Chun J, Han K, Kim Y, Kim R, Park MC, Kim JH, Youn YH, Park H. Kwon OC, et al. Front Med (Lausanne). 2023 Jun 20;10:1185300. doi: 10.3389/fmed.2023.1185300. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37409280 Free PMC article.

3

Application of recombinant antibodies for treatment of Clostridioides difficile infection: Current status and future perspective.

Raeisi H, Azimirad M, Nabavi-Rad A, Asadzadeh Aghdaei H, Yadegar A, Zali MR. Raeisi H, et al. Front Immunol. 2022 Aug 23;13:972930. doi: 10.3389/fimmu.2022.972930. eCollection 2022. Front Immunol. 2022. PMID: 36081500 Free PMC article. Review.

4

The Perspective of Therapeutic Antibody Marketing in Iran: Trend and Estimation by 2025.

Golpour M, Vatanpour P, Amini M, Saeedi M, Hafezi N, Rafiei A. Golpour M, et al. Adv Pharmacol Pharm Sci. 2021 Mar 30;2021:5569590. doi: 10.1155/2021/5569590. eCollection 2021. Adv Pharmacol Pharm Sci. 2021. PMID: 33860229 Free PMC article.

5

A Randomized, Double-Blind, Parallel-Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects.

Cao G, Yu J, Wu J, Wang J, Xue Y, Yang X, Zhang J. Cao G, et al. Clin Pharmacol Drug Dev. 2021 Mar;10(3):317-325. doi: 10.1002/cpdd.816. Epub 2020 May 28. Clin Pharmacol Drug Dev. 2021. PMID: 32463599 Free PMC article. Clinical Trial.

6

Long-term treatment of rheumatoid arthritis with adalimumab.

Murdaca G, Spanò F, Puppo F. Murdaca G, et al. Open Access Rheumatol. 2013 May 7;5:43-49. doi: 10.2147/OARRR.S32582. eCollection 2013. Open Access Rheumatol. 2013. PMID: 27790023 Free PMC article. Review.

7

Vaccine-preventable infections in Systemic Lupus Erythematosus.

Murdaca G, Orsi A, Spanò F, Faccio V, Puppo F, Durando P, Icardi G, Ansaldi F. Murdaca G, et al. Hum Vaccin Immunother. 2016 Mar 3;12(3):632-43. doi: 10.1080/21645515.2015.1107685. Hum Vaccin Immunother. 2016. PMID: 26750996 Free PMC article. Review.

8

TNF-α gene polymorphisms: association with disease susceptibility and response to anti-TNF-α treatment in psoriatic arthritis.

Murdaca G, Gulli R, Spanò F, Lantieri F, Burlando M, Parodi A, Mandich P, Puppo F. Murdaca G, et al. J Invest Dermatol. 2014 Oct;134(10):2503-2509. doi: 10.1038/jid.2014.123. Epub 2014 Mar 4. J Invest Dermatol. 2014. PMID: 24594669 Free article.

9

Targeting F box protein Fbxo3 to control cytokine-driven inflammation.

Mallampalli RK, Coon TA, Glasser JR, Wang C, Dunn SR, Weathington NM, Zhao J, Zou C, Zhao Y, Chen BB. Mallampalli RK, et al. J Immunol. 2013 Nov 15;191(10):5247-55. doi: 10.4049/jimmunol.1300456. Epub 2013 Oct 11. J Immunol. 2013. PMID: 24123678 Free PMC article.

10

Free radicals and endothelial dysfunction: potential positive effects of TNF-α inhibitors.

Murdaca G, Spanò F, Cagnati P, Puppo F. Murdaca G, et al. Redox Rep. 2013;18(3):95-9. doi: 10.1179/1351000213Y.0000000046. Epub 2013 May 10. Redox Rep. 2013. PMID: 23676793 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

13 results

Results by year